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Introduction: This study aimed to investigate rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA)
status and levels as predictors of mortality in two large cohorts of patients with early inflammatory arthritis (EIA).
Methods: Data from the Norfolk Arthritis Register (NOAR) and Leiden Early Arthritis Clinic (EAC) cohorts were used.
At baseline, patients had demographic data and smoking status recorded; RF, ACPA and inflammatory markers were
measured in the local laboratories. Patients were flagged with national death registers until death or censor date.
Antibody status was stratified as negative, low or high positive by RF and ACPA levels individually. In addition,
patients were grouped as seronegative, RF positive, ACPA positive or double antibody (RF and ACPA) positive. Cox
regression models explored associations between antibody status and mortality adjusting for age, sex, smoking
status, inflammatory markers and year of enrolment.
Results: A total of 4962 patients were included, 64% were female. Median age at onset was 56 (NOAR) and 54
(EAC) years. In NOAR and EAC respectively, 35% and 42% of patients were ACPA/RF positive. When antibody status
was stratified as negative, low or high positive, there were no consistent findings between the two cohorts. Double
antibody positivity was associated with excess mortality in both cohorts compared to seronegative patients: NOAR
and EAC respective adjusted HR (95% confidence interval) 1.35 (1.09 to 1.68) and 1.58 (1.16 to 2.15).
Conclusions: Patients with EIA who are seropositive for both RF and ACPA have increased mortality compared to
those who are single positive or seronegative. Antibody level in seropositive patients was not consistently
associated with excess mortality.Introduction
In patients with inflammatory arthritis, the auto-
antibodies rheumatoid factor (RF) and anti-citrullinated
protein antibody (ACPA) have been associated with poor
outcomes, such as increased disease activity, radio-
graphic progression and disability [1-5]. However, the
utility of antibody level in predicting the prognosis of* Correspondence: suzanne.verstappen@manchester.ac.uk
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article, unless otherwise stated.inflammatory arthritis, in particular rheumatoid arthritis
(RA), has not been clearly established. In a recent multi-
centre prospective study of patients with early inflam-
matory arthritis (EIA), the presence of RF and/or ACPA
was a significant predictor of RA diagnosis within two
years, but level did not appear to be important [6]. In
contrast, in a study of patients with EIA from Norway in
2010, Mjaavatten et al. found that increasing levels of RF
and ACPA were associated with persistent joint in-
flammation [7]. Other studies have failed to show
consistently that either RF or ACPA antibody level isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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EIA and RA [8-10]. In addition, recent data from a sub-
set of the Leiden Early Arthritis Clinic have shown that
the avidity of ACPA may be prognostically more impor-
tant than the level itself [11].
Nevertheless, antibody level is included in the 2010
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classification cri-
teria for RA [12], which aim to identify those patients
with EIA with poor prognosis sufficient to require inter-
vention with disease modifying therapy. The presence of
RF and ACPA are weighted as part of the total score ac-
cording to their level; patients are said to be low positive
if their level is greater than the upper limit of normal
(ULN) but less than three times the ULN, and high posi-
tive if their level is at least three times the ULN. Thus,
patients with high antibody levels are more likely to fulfil
the criteria, and it would be interesting to investigate
whether these cut-offs are appropriate in predicting
other adverse outcomes, such as mortality.
The increased mortality in patients with RA has been
long established [13]. It is also well recognised that the
presence of RF in sera of patients with inflammatory
arthritis (whether or not they meet formal classification
criteria for RA) is associated with an increased risk of
premature death [14-16]. In fact, this association has
been demonstrated even in subjects without symptoms
of arthritis [17]. ACPA positivity has also been shown to
predict premature mortality in the Norfolk Arthritis
Register [18]; however this association has yet to be con-
firmed in other cohorts.
The aims of this study were to investigate the asso-
ciation between mortality and RF and/or ACPA positiv-
ity and level in patients with EIA. The term EIA
includes all patients with RA early in the disease process,
and studying these patients allows additional inclusion
of those patients who may later go on to meet formal
classification criteria for RA. It has been recognised that
significant variability in antibody testing can occur bet-
ween laboratories [19]. Thus, to strengthen the external
validity of the study results, we investigated these ques-
tions in two large prospective cohorts of patients with
EIA: the Norfolk Arthritis Register (NOAR) in the UK and
the Leiden Early Arthritis Clinic (EAC) in the Netherlands.
Methods
Patients and setting
Patients in Norfolk, UK, were recruited to NOAR be-
tween 1990 and 2009 from primary and secondary care
if they were adults (≥16 years) and had ≥2 swollen joints
for ≥4 weeks; NOAR has been described in detail else-
where [20]. Leiden EAC has also been described pre-
viously [21]; briefly patients in the region of Leiden, the
Netherlands, with synovitis confirmed by a rheumatologistwere recruited to the Leiden EAC from 1993 onwards if
their symptom duration was less than two years at presen-
tation. In order to make the two cohorts as comparable as
possible, patients in NOAR were only included in this
study if they had symptom duration of less than two years
at presentation.
Assessment and follow up
Patients in NOAR are assessed at baseline by a research
nurse who administers a structured questionnaire, inclu-
ding demographic details as well as disease and smoking
history (never, past, current), performs a 51 tender and
swollen joint count and obtains a blood sample. Sera are
stored frozen and tested for C-reactive protein (CRP) and
RF (latex test, low positive cut-off 40 units/ml, high posi-
tive cut-off 120 units/ml); subsequently ACPA, as defined
by anti-CCP2 antibodies, are tested for using the Axis-
Shield, Dundee, UK Diastat Anti-CCP kit (low positive cut-
off 5 units/ml, high positive cut-off 15 units/ml). The Lei-
den EAC initial assessment includes medical history, clin-
ical examination and joint counts. Blood samples are
taken and tested for erythrocyte sedimentation rate (ESR),
RF (IgM-RF in-house ELISA, low positive cut-off 5 units/
ml, high positive cut-off 15 unit/ml) and ACPA
(AntiCCP-2, Euro-Diagnostica, Malmo, Sweden Immu-
noscanRA Mark 2, low positive cut-off 25 units/ml, high
positive cut-off 75 units/ml). All cut-offs used are those
recommended by the relevant manufacturers. Patients in
NOAR are flagged with the NHS Information Centre
(NHS IC) from baseline. NHS IC provide copies of death
certificates to NOAR with approximately six months lag
in reporting. They also provide a date of ‘embarkation’ for
patients who leave the UK. Mortality data on patients re-
cruited to the EAC are tracked nationally using the civic
registries (Gemeentelijke Basis Administratie) in the
Netherlands. NOAR is approved by Norfolk and Norwich
University Hospital Local Research Ethics Committee UK,
and EAC was approved by the local medical ethics com-
mittee LUMC The Netherlands.
Statistical analysis
Antibody levels were divided into negative, low positive
and high positive as defined by the 2010 classification cri-
teria [12]. These cut-offs were selected to investigate the
ability of this aspect of the criteria to predict mortality.
NOAR patients were censored for analysis at date of
death, date of embarkation or 30 June 2012, whichever
came first. Leiden EAC patients were censored at date of
death or 1 May 2012. Analyses were conducted separately
in each cohort. Kaplan-Meier survival curves were used to
compare survival univariately in patients grouped accor-
ding to their antibody status. Cox proportional hazard
models were used to investigate the association between
antibody status, antibody level and subsequent mortality.
Table 1 Demographic and baseline disease characteristics
Demographic/characteristic NOAR Leiden EAC
number = 3,053 number = 1,909
Female number (%) 1970 (65) 1205 (63)
Age at symptom onset (years)
median (IQR)
56 (44 to 68) 54 (42 to 67)
Symptom duration (weeks)
median (IQR)
26 (14 to 47) 17 (8 to 33)
RF/ACPA positive umbern (%) 1079 (35) 810 (42)
RF positive 912 (34) 704 (37)
RF low positive 315 (12) 256 (13)
RF high positive 594 (22) 445 (23)
ACPA positive 598 (27) 591 (31)
ACPA low positive 91 (4) 66 (3.5)
ACPA high positive 507 (23) 532 (27.9)
Inflammatory marker
(CRP, mg/L)
9 (2 to 20) -
Inflammatory marker
(ESR, mm/hr)
- 25 (11 to 44)
Smoking status
Never 998 (33) 740 (45)
Previous 1189 (39) 445 (27)
Current 748 (26) 450 (28)
2010 ACR/EULAR RA criteria
positive number (%)
1701 (63) 1073 (57)
1987 ACR RA criteria positive
number (%)
1303 (43) 736 (39)
Categorical variables are presented as number (% non-missing data). % percentage
missing values for NOAR and Leiden EAC, respectively, were as follows; RF/ACPA
10% and 0.5%, RF 11 % and 1%, ACPA 27% and 12%, CRP 18%, ESR 1%, smoking
status 4% and 14%, 2010 RA 11% and 1%, 1987 RA 0.5% and 0%. ACPA,
anti-citrullinated protein antibodies; ACR, American College of Rheumatology;
CRP, C-reactive protein; EAC, Early Arthritis Clinic; ESR, erythrocyte sedimentation
rate; EULAR European League Against Rheumatism; IQR, inter-quartile range;
NOAR, Norfolk Arthritis Register; RF, rheumatoid factor; RA, rheumatoid arthritis.
The italicised words describe how each characteristic is being presented
numerically rather than the name of the characteristic itself, and are therefore
italicised for clarity to make that distinction.
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tients were categorised according to antibody status as
negative, low positive or high positive, and two models
were then developed considering RF and ACPA status
separately. A third model investigated whether the pre-
sence (above the ULN) of both antibodies, rather than
antibody level, was important in predicting mortality by
categorising patients as seronegative, RF single antibody
positive, ACPA single antibody positive and double anti-
body positive (that is, both RF and ACPA positive). Uni-
variate models were constructed initially, then age and sex
adjusted; finally a multivariate model was developed ad-
justing for age, gender, baseline smoking status (cate-
gorised as current, ever or never smokers), inflammatory
marker (ESR in EAC or CRP in NOAR) level, and year of
enrolment to the cohort as a proxy for changing treatment
strategies over time. All analyses were repeated in the
population of patients fulfilling the 2010 ACR/EULAR cri-
teria for RA. We aimed to focus on the predictive proper-
ties of the antibodies specifically and were deliberately
parsimonious with our variable selection in the multiva-
riate model. Thus, if a variable was not considered a con-
founder a priori, that is, would not have associations with
both antibody status and mortality, it was not included.
Similarly, variables that might be on the causal pathway
between antibody status and mortality (such as disease ac-
tivity over time) were also not included, as the relationship
between antibody status and disease activity can only
occur in one direction.
In the model in which the presence of both antibodies
was compared to single antibody positivity and sero-
negativity, only patients who had been tested for both
antibodies were included. In NOAR, 2,195 (72%) pa-
tients had data on both antibodies; data were more
complete for the EAC, where 1,663 (87%) had both anti-
bodies measured. In NOAR, therefore, baseline charac-
teristics of patients with and without complete antibody
data were assessed for differences. In addition, in order
to ensure that the reported results were representative,
multiple imputation using chained equations was per-
formed to impute the antibody status of those patients
with missing data. A subsequent sensitivity analysis was
performed using the imputed dataset and these results
were compared with those from the complete case ana-
lysis. Data from NOAR were analysed using the Stata 11
software package (Stata, College Station, TX, USA), data
from EAC were analysed using SPSS for Windows ver-
sion 20.0 (SPSS, Chicago, IL, USA).
Results
A total of 4,962 patients with EIA were included in the
study (3,053 from NOAR, 1,909 from Leiden EAC). The
cohorts had similar age and gender distributions, 65%
(1,970) female in NOAR, 63% (1,205) female in the EAC,respective median (interquartile range) age at symptom
onset 56 (44 to 68) and age at inclusion 54 (42 to 67)
years. In NOAR, 63% of patients fulfilled the 2010 ACR/
EULAR classification criteria for RA, in the EAC this pro-
portion was 57% of patients. Baseline characteristics of pa-
tients from the two cohorts are shown in Table 1. The
mean (standard deviation) follow up in each study was
11.8 (5.8) years in NOAR and 8.5 (5.2) years in EAC.
There were 787 deaths during 36,109 person years follow
up in NOAR, and 275 deaths during 16,187 person years
follow up in the EAC; this resulted in crude death rates of
21.8 and 17.0 deaths per 1,000 person years in each co-
hort, respectively. The number of deaths in each of the
antibody subgroups are shown in Table 2.
Table 2 Number of deaths in each antibody group
Antibody group NOAR Leiden EAC
RF/ACPA negative 401 28
RF/ACPA low positive 39 40
RF/ACPA high positive 264 106
RF negative 444 137
RF low positive 52 54
RF high positive 202 82
ACPA negative 394 154
ACPA low positive 21 17
ACPA high positive 156 86
Both antibodies negative 339 119
RF positivea 47 35
ACPA positivea 51 9
Both antibodies positive 128 93
aWhere patients had both antibodies tested. ACPA, anti-citrullinated peptide
antibodies; EAC, Early Arthritis Clinic; NOAR, Norfolk Arthritis Register;
RF, rheumatoid factor.
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The first Cox proportional hazards models (univariate
and adjusted) examined RF and ACPA levels separately
(Table 3). There appeared to be a marked difference in RF
high and low positivity in the NOAR cohort: low positive
RF adjusted hazard ratio (HR) (95% confidence interval
(CI)) 0.80 (0.59 to 1.08), high positive RF adjusted HR
(95% CI) 1.49 (1.25 to 1.77). However, this was not repli-
cated in the EAC cohort: low positive RF adjusted HR
(95% CI) 1.62 (1.16 to 2.26), high positive RF adjusted HR
(95% CI) 1.63 (1.19 to 2.24). Differences between the two
cohorts were also seen with ACPA (Table 3). In the EAC,
low positive ACPA status was associated with increased
mortality, but high positive ACPA was not, respective ad-
justed HR (95% CI) 2.21 (1.31 to 3.72) and 1.25 (0.93 to
1.69). Conversely, in NOAR there was a trend towards in-
creased mortality in the low positive ACPA group, and
high positive ACPA status was significantly associated, ad-
justed HR (95% CI) 1.32 (1.08 to 1.61). Of note, there were
only a small number of patients and, therefore, deaths in
the ACPA low positive group in either cohort: 21 deaths
in NOAR and 17 in the EAC. Similar findings were ob-
served in the population of patients fulfilling the 2010
ACR/EULAR criteria for RA, although not always rea-
ching statistical significance, probably due to smaller
group sizes. Data on the full multivariate models are avail-
able as part of Additional file 1. The Additional file 1 also
includes a model comparing patients negative for both
antibodies to those with low and high levels of either anti-
body and models dividing RF and ACPA levels into tertiles
rather than using the predefined cut-offs of the 2010 cri-
teria. These additional models demonstrated similar re-
sults to those reported here.Number of antibodies
This Cox model stratified patients by the number of
antibodies present (negative, RF positive, ACPA positive,
and double antibody positive if both RF and ACPA were
positive). The results were more consistent between the
two cohorts (Table 4 and Figure 1) and between the total
EIA population and the 2010 ACR/EULAR RA popula-
tion. In both NOAR and the EAC there was a trend to-
wards increased mortality in patients who had a single
positive antibody compared to no positive antibodies,
other than single ACPA positivity in the Leiden EAC,
where the number of deaths was small. In both cohorts
the presence of two positive antibodies was significantly
associated with increased mortality, adjusted HRs (95% CI)
NOAR: 1.35 (1.09 to 1.68), EAC: 1.57 (1.15 to 2.14). No
differences were identified in the baseline characteristics
of patients with missing data in NOAR for this model, and
the sensitivity analysis using imputed data produced simi-
lar results to the complete case analysis [see Additional
file 1].
Discussion
In two well established observational cohorts of EIA and
its sub-population of patients with RA, we have shown
that RF and ACPA positivity are predictors of excess
mortality, and that the presence of both antibodies was a
stronger predictor of mortality than single antibody posi-
tivity. However, in this first large study to investigate the
association between antibody levels and mortality, the
influence of increasing antibody level was not consistent
between the two cohorts.
Our data have once again demonstrated the known re-
lationship between RF positivity and early mortality [14],
and confirmed that a similar association exists in pa-
tients who are ACPA positive. This has previously been
described in NOAR [18] but only reported elsewhere by
two other groups of investigators. The first study was in
a subset of 299 patients in the Rochester epidemiology
project [22], half of whom had RA. The second small
study, by Sihvonen et al. [23] used logistic regression
(which does not allow for censoring) rather than Cox
models to analyse the data. It was, therefore, important
to corroborate this association in another large EIA co-
hort, such as the Leiden EAC.
The results of our study are concordant with the fin-
dings of Ursum et al., who studied 545 patients with
early arthritis in the Netherlands [10]. They found no as-
sociation after two years between antibody levels and early
disease outcomes, including disease activity measured by
DAS28, functional status measured by the Health Assess-
ment Questionnaire (HAQ) and radiographic progression.
Similarly, a number of other small studies have reinforced
the association between ACPA positivity and other poor
outcomes, such as increased disease activity and
Table 3 Comparison of patients RF or ACPA negative to those with low and high RF or ACPA levels
NOAR Leiden EAC
Total EIA population 2010 ACR/EULAR positive cohort Total EIA population 2010 ACR/EULAR positive cohort
Model/predictor HR 95% CI HR 95% CI HR 95% CI HR 95% CI
RF:
Unadjusteda
RF low positive 0.90 0.68 to 1.20 0.90 0.66 to 1.24 2.13 1.55 to 2.91 1.75 1.21 to 2.54
RF high positive 1.67 1.41 to 1.97 1.43 1.18 to 1.74 1.75 1.33 to 2.31 1.39 0.99 to 1.93
Age and sex adjusteda
RF low positive 0.81 0.61 to 1.08 0.80 0.58 to 1.10 1.67 1.21 to 2.29 1.67 1.15 to 2.42
RF high positive 1.54 1.30 to 1.82 1.33 1.09 to 1.62 1.92 1.46 to 2.53 2.00 1.42 to 2.81
Multivariateab
RF low positive 0.80 0.59 to 1.08 0.85 0.61 to 1.18 1.62 1.16 to 2.26 1.57 1.07 to 2.32
RF high positive 1.49 1.25 to 1.77 1.40 1.14 to 1.71 1.63 1.19 to 2.24 1.68 1.16 to 2.44
ACPA:
Unadjustedc
ACPA low positive 1.05 0.68 to 1.63 0.98 0.61 to 1.59 1.65 1.00 to 2.72 0.97 0.54 to 1.73
ACPA high positive 1.49 1.24 to 1.79 1.27 1.03 to 1.57 1.17 0.90 to 1.52 0.79 0.58 to 1.06
Age and sex adjustedc
ACPA low positive 1.16 0.75 to 1.81 1.19 0.73 to 1.93 2.52 1.52 to 4.18 1.99 1.10 to 3.61
ACPA high positive 1.41 1.17 to 1.69 1.29 1.04 to 1.59 1.45 1.11 to 1.90 1.37 1.00 to 1.89
Multivariatecb
ACPA low positive 1.39 0.89 to 2.16 1.44 0.89 to 2.36 2.21 1.31 to 3.72 1.78 0.96 to 3.28
ACPA high positive 1.32 1.08 to 1.61 1.24 0.99 to 1.57 1.25 0.93 to 1.69 1.22 0.86 to 1.73
aRF negative was used as a reference group; badjusted for age at symptom onset, sex, baseline smoking status, year of inclusion in cohort and inflammatory
marker; cACPA negative was used as a reference group. Inflammatory marker = C-reactive protein in NOAR, = erythrocyte sedimentation rate in EAC. ACPA,
anti-citrullinated protein antibodies; CI, confidence interval; HR, hazard ratio; RF, rheumatoid factor. The bold and italic text indicates subtitles, hence why there
are no values in the table next to them. It is therefore essential that they look different to the predictor variables and the result values themselves.
Table 4 RF and ACPA positive versus single positive and both antibodies negative
NOAR Leiden EAC
Total EIA population 2010 ACR/EULAR positive cohort Total EIA population 2010 ACR/EULAR positive cohort
Model/predictor HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Unadjusted
RF positive 1.11 0.83 to 1.49 1.10 0.79 to 1.53 1.88 1.29 to 2.74 1.53 0.99 to 2.36
ACPA positive 1.27 0.94 to 1.73 1.14 0.82 to 1.59 0.63 0.32 to 1.23 0.31 0.13 to 0.73
Both antibodies positive 1.51 1.23 to 1.85 1.29 1.02 to 1.64 1.59 1.21 to 2.09 1.12 0.80 to 1.57
Age and sex adjusted
RF positive 1.05 0.78 to 1.41 1.10 0.79 to 1.54 1.45 0.99 to 2.13 1.54 0.99 to 2.37
ACPA positive 1.40 1.03 to 1.91 1.42 1.02 to 1.99 0.96 0.48 to 1.90 0.71 0.30 to 1.68
Both antibodies positive 1.38 1.12 to 1.69 1.25 0.99 to 1.59 1.82 1.38 to 2.40 1.83 1.29 to 2.60
Multivariatea
RF positive 1.11 0.82 to 1.51 1.22 0.87 to 1.72 1.48 0.99 to 2.21 1.47 0.94 to 2.30
ACPA positive 1.35 0.98 to 1.88 1.39 0.97 to 1.99 1.05 0.53 to 2.09 0.79 0.33 to 1.89
Both antibodies positive 1.35 1.09 to 1.68 1.31 1.01 to 1.69 1.57 1.15 to 2.14 1.59 1.08 to 2.32
aAdjusted for age at symptom onset, sex, baseline smoking status, year of inclusion in cohort and inflammatory marker; both antibodies negative was used as
reference group; inflammatory marker = C-reactive protein in NOAR, = erythrocyte sedimentation rate in EAC. ACPA, anti-citrullinated protein antibodies;
CI, confidence interval; HR, hazard ratio; RF, rheumatoid factor. The bold and italic text indicates subtitles, hence why there are no values in the table next to them.
It is therefore essential that they look different to the predictor variables and the result values themselves.
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Figure 1 Unadjusted survival curves stratified by number of antibodies.
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ation with increasing ACPA levels [8,24]. By contrast,
Syversen et al. conducted a study of 125 patients who met
the 1987 ACR classification criteria for RA [25] in a sub-
population of the European Research on Incapacitating
Disease and Social Support (EURODISS) project [26].
They found that 10 year radiographic progression was in-
creased in patients with low-moderate ACPA levels
(>ULN and ≤8 times ULN), but this appeared to be fur-
ther increased in patients with very high levels of ACPA
(>8 times the ULN). However, they also demonstrated that
the highest probability of radiographic progression oc-
curred in patients who were positive for both RF and
ACPA. A recent study in Italy examined progression from
EIA to RA in 192 patients [6]. In accordance with our
findings, they demonstrated the presence of both anti-
bodies predicted RA, but antibody high or low positivity
had no influence. In the Norwegian Very Early Arthritis
Clinic (NOR-VEAC) study, Mjaavatten et al. showed addi-
tive value in testing for both antibodies in order to predict
disease persistence [7]. They also demonstrated an associ-
ation between antibody level and persistent arthritis, how-
ever the number of patients per group was small (<30). In
addition, their analysis employed last observation carried
forward to account for patients who did not have
complete follow up. It is possible, therefore, that their re-
sults were influenced by attrition bias; that is, patients
whose arthritis resolved may not have attended further
follow up, and at their last recorded visit, their arthritis ap-
peared to be persistent even though it subsequently re-
solved. It is possible that the different characteristics and
follow up of these cohorts account for the different find-
ings; in addition the different cut-offs of the commerciallyavailable assays may not correspond. Nevertheless, this
emphasises that the role of antibody levels in predicting
outcomes for patients with inflammatory arthritis has not
been robustly established.
There are limitations to our study. We decided not to
perform a pooled analysis of data from both cohorts be-
cause the different inclusion criteria of the two cohorts
could potentially produce misleading conclusions. We
did not aim to develop a full predictive model for mor-
tality in RA, but focussed specifically on the association
between antibody status and level, and mortality. There-
fore, the number of confounders included in the multi-
variate model was small, and the final model does not
account for all predictors of mortality in RA. As in
all observational studies, there remains potential for re-
sidual confounding for which we have not adjusted. Fur-
ther, in our analyses we did make the assumption that
antibody status is fixed. This assumption seemed reason-
able as the majority of studies have shown for both RF
and, particularly, ACPA, that few patients convert from
seropositive to negative over time [27-29], and when
this does occur, risk of poor outcome may be main-
tained [30].
Conclusions
In conclusion, in this large study investigating the rela-
tionship between antibody levels and mortality in EIA,
we have shown that patients with both RF and ACPA,
rather than the higher levels of the antibodies, had in-
creased rates of early death. We have also confirmed the
association between ACPA positivity and excess mortal-
ity in a second large EIA cohort. Therefore, in patients
presenting with early rheumatoid arthritis, the number
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antibody levels in assessing the mortality risk in clinical
practice.
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Additional file 1: Table S1. Univariate and multivariate Cox
proportional hazard models comparing RF/ACPA high/low positive versus
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Table S3. Comparison of RF or ACPA levels in tertiles. Table S4.
Univariate and multivariate Cox proportional hazard models comparing
RFand ACPA positive versus single positive and both antibodies negative.
Table S5. Sensitivity analysis with imputed data.
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